140 related articles for article (PubMed ID: 32126433)
1. Daratumumab for quick and sustained remission in post-transplant relapsed/refractory acute lymphoblastic leukemia.
Zhang Y; Xue S; Liu F; Wang J
Leuk Res; 2020 Apr; 91():106332. PubMed ID: 32126433
[No Abstract] [Full Text] [Related]
2. Prognosis of haploidentical hematopoietic stem cell transplantation in non-infant children with t(v;11q23)/MLL-rearranged B-cell acute lymphoblastic leukemia.
Bai L; Cheng YF; Lu AD; Suo P; Wang Y; Zuo YX; Yan CH; Wu J; Jia YP; Sun YQ; Chen YH; Chen H; Liu KY; Han W; Xu LP; Wang JB; Tang XF; Chen HR; Zhang LP; Huang XJ
Leuk Res; 2020 Apr; 91():106333. PubMed ID: 32109757
[TBL] [Abstract][Full Text] [Related]
3. Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.
Chevallier P; Chantepie S; Huguet F; Raffoux E; Thomas X; Leguay T; Marchand T; Isnard F; Charbonnier A; Maury S; Gallego-Hernanz MP; Robillard N; Guillaume T; Peterlin P; Garnier A; Rialland F; Le Houerou C; Goldenberg DM; Wegener WA; Béné MC; Dombret H
Haematologica; 2017 May; 102(5):e184-e186. PubMed ID: 28154086
[No Abstract] [Full Text] [Related]
4. Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia.
Papayannidis C; Derenzini E; Iacobucci I; Curti A; Paolini S; Cilloni D; Baccarani M; Martinelli G
Am J Hematol; 2009 Dec; 84(12):849-50. PubMed ID: 19844989
[No Abstract] [Full Text] [Related]
5. Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study.
Chevallier P; Huguet F; Raffoux E; Etienne A; Leguay T; Isnard F; Robillard N; Guillaume T; Delaunay J; Charbonnier A; Pigneux A; Peterlin P; Bené MC; Wegener WA; Goldenberg DM; Dombret H
Haematologica; 2015 Apr; 100(4):e128-31. PubMed ID: 25552705
[No Abstract] [Full Text] [Related]
6. Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia.
Claviez A; Eckert C; Seeger K; Schrauder A; Schrappe M; Henze G; von Stackelberg A
Haematologica; 2006 Feb; 91(2):272-3. PubMed ID: 16461321
[TBL] [Abstract][Full Text] [Related]
7. Regeneration pattern of precursor-B-cells in bone marrow of acute lymphoblastic leukemia patients depends on the type of preceding chemotherapy.
van Lochem EG; Wiegers YM; van den Beemd R; Hählen K; van Dongen JJ; Hooijkaas H
Leukemia; 2000 Apr; 14(4):688-95. PubMed ID: 10764156
[TBL] [Abstract][Full Text] [Related]
8. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.
Valecha GK; Ibrahim U; Ghanem S; Asti D; Atallah JP; Terjanian T
Expert Rev Hematol; 2017 Sep; 10(9):783-799. PubMed ID: 28666090
[TBL] [Abstract][Full Text] [Related]
9. Management of patients with acute lymphoblastic leukemia in routine clinical practice: Minimal residual disease testing, treatment patterns and clinical outcomes in Belgium, Greece and Switzerland.
Deeren D; Balabanov S; Nickel K; Giannopoulou C; Gonzalez-McQuire S; Kutikova L; Bouwmeester W; Spyridonidis A
Leuk Res; 2020 Apr; 91():106334. PubMed ID: 32135394
[TBL] [Abstract][Full Text] [Related]
10. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphoblastic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
Büyükçelik A; Yalçin B; Utkan G; Doruk H
Cancer; 2004 Sep; 101(5):1100-1; author reply 1101. PubMed ID: 15329922
[No Abstract] [Full Text] [Related]
11. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.
Pan J; Yang JF; Deng BP; Zhao XJ; Zhang X; Lin YH; Wu YN; Deng ZL; Zhang YL; Liu SH; Wu T; Lu PH; Lu DP; Chang AH; Tong CR
Leukemia; 2017 Dec; 31(12):2587-2593. PubMed ID: 28490811
[TBL] [Abstract][Full Text] [Related]
12. CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia.
Liu J; Zhang X; Zhong JF; Zhang C
Immunotherapy; 2017 Oct; 9(13):1115-1125. PubMed ID: 29032733
[TBL] [Abstract][Full Text] [Related]
13. A pilot study of daunorubicin-augmented hyper-CVAD induction chemotherapy for adults with acute lymphoblastic leukemia.
Kim SY; Park JH; Yoon SY; Cho YH; Lee MH
Cancer Chemother Pharmacol; 2018 Feb; 81(2):393-398. PubMed ID: 29294168
[TBL] [Abstract][Full Text] [Related]
14. Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis.
El-Cheikh J; El Dika I; Massoud R; Charafeddine M; Mahfouz R; Kharfan-Dabaja MA; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):179-185. PubMed ID: 27988194
[TBL] [Abstract][Full Text] [Related]
15. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
Weiser MA; O'Brien S; Thomas DA; Pierce SA; Lam TP; Kantarjian HM
Cancer; 2002 Jan; 94(2):285-91. PubMed ID: 11900213
[TBL] [Abstract][Full Text] [Related]
17. Case Report: Humanized Selective CD19CAR-T Treatment Induces MRD-Negative Remission in a Pediatric B-ALL Patient With Primary Resistance to Murine-Based CD19CAR-T Therapy.
Wang K; Zhao Y; Wang X; Wang B; Qin M; Zhu G; Wu H; Liu Z; Zheng X; Zheng H; Chen Z
Front Immunol; 2020; 11():581116. PubMed ID: 33424835
[TBL] [Abstract][Full Text] [Related]
18. The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.
McGregor BA; Brown AW; Osswald MB; Savona MR
Am J Hematol; 2009 Apr; 84(4):228-30. PubMed ID: 19260120
[TBL] [Abstract][Full Text] [Related]
19. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
[TBL] [Abstract][Full Text] [Related]
20. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]